| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & Chief Operating Officer | President & Chief Comm. Officer
1 company
David Pernock last filed a Form 4 in February 2021, as President & Chief Operating Officer at EGRX. David Pernock's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 54,625 shares of EGRX. Net of sales, the EGRX filings show accumulation of 966 shares.
David Pernock has 16 Form 4 filings on record from April 2015 to February 2021, all as President & Chief Operating Officer at Eagle Pharmaceuticals (EGRX), 2015–2021.
The 22 reported transactions were 8 option or other derivative awards, 6 tax withholdings, 4 stock awards and 4 open-market purchases.
Counted by filing, the open-market trades come to 4 purchases worth about $77K and no sales.
The largest open-market purchase was 450 shares of EGRX at an average $77.84 on March 9, 2017, about $35K.
Shares as reported in the last Form 4 for each company; the most recent is from February 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 19, 2017 | EGRX Eagle Pharmaceuticals, Inc. | President & Chief Comm. Officer | Buy | 255 | $79.69 | $20,320.95 | +35.9% | |
| May 16, 2017 | EGRX Eagle Pharmaceuticals, Inc. | President & Chief Comm. Officer | Buy | 200 | $82.24 | $16,448.00 | +39.1% | |
| Mar 21, 2017 | EGRX Eagle Pharmaceuticals, Inc. | President & Chief Comm. Officer | Buy | 61 | $83.98 | $5,122.78 | +13.6% | |
| Mar 9, 2017 | EGRX Eagle Pharmaceuticals, Inc. | President & Chief Comm. Officer | Buy | 450 | $77.84 | $35,028.49 | New |